NBIX - Neurocrine Biosciences, Inc.
100.08 0.00 (0.00%)
After hours: 4:13PM EDT
| Previous Close | 100.83 |
| Open | 100.80 |
| Bid | 100.05 x 900 |
| Ask | 100.10 x 800 |
| Day's Range | 100.01 - 101.94 |
| 52 Week Range | 64.72 - 125.59 |
| Volume | 545,805 |
| Avg. Volume | 664,150 |
| Market Cap | 9.165B |
| Beta (3Y Monthly) | 1.05 |
| PE Ratio (TTM) | 549.89 |
| EPS (TTM) | 0.18 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 111.33 |
- Zacks
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
- PR Newswire
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
- Phase III Data Analyses Evaluate the Long-Term Benefit of INGREZZA® (valbenazine) 40 mg and Early Response to Treatment in Patients with Tardive Dyskinesia - Data Examine Effect of Opicapone on COMT ...
- PR Newswire
Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors
SAN DIEGO , Sept. 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Leslie V. Norwalk to its Board of Directors. Ms. Norwalk formerly served as Acting ...
- Zacks
HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now?
HKMPF vs. NBIX: Which Stock Is the Better Value Option?
- Zacks
Lannett (LCI) Hits 52-Week High, Can the Run Continue?
Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- PR Newswire
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
Matt Abernethy, Chief Financial Officer, will present at the Baird 2019 Global Healthcare Conference at 8:30 a.m. ET on Wednesday, Sept. 4, 2019, in New York. Kevin Gorman, Chief Executive Officer, will present at the Morgan Stanley 17th Annual Healthcare Conference at 11:10 a.m. ET on Tuesday, Sept. 10, 2019, in New York. The live presentations will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com.
- Zacks
Is Neurocrine Biosciences (NBIX) a Great Growth Stock?
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Neurocrine Biosciences (NBIX).
- Thomson Reuters StreetEvents
Edited Transcript of NBIX earnings conference call or presentation 29-Jul-19 8:30pm GMT
Q2 2019 Neurocrine Biosciences Inc Earnings Call
- Simply Wall St.
Should You Be Worried About Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) 3.7% Return On Equity?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Zacks
Another 1% Rally Provides a Strong Start to the Week
Another 1% Rally Provides a Strong Start to the Week
- Zacks
Why Neurocrine (NBIX) Could Be Positioned for a Surge
Neurocrine (NBIX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
- Zacks
Moving Average Crossover Alert: Neurocrine Biosciences
Neurocrine Biosciences, Inc. (NBIX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- Zacks
Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.
- Zacks
Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
- Zacks
Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
Esperion Therapeutics (ESPR) reports mixed second-quarter results.
- GuruFocus.com
Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $7.6 million of Shares
CEO of Neurocrine Biosciences Inc (30-Year Financial, Insider Trades) Kevin Charles Gorman (insider trades) sold 80,000 shares of NBIX on 08/08/2019 at an average price of $95.31 a share. Continue reading...
- Zacks
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.
- PR Newswire
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
- New Drug Application (NDA) is supported by data from pivotal Phase 3 studies of nearly 800 patients - Clinical trials in women with heavy menstrual bleeding (HMB) associated with uterine fibroids showed ...
- GuruFocus.com
Steven Cohen Charges Into Chiasma
Guru invests in clinical-stage biopharmaceutical company Continue reading...
- Zacks
Why Neurocrine (NBIX) Might be Well Poised for a Surge
Neurocrine (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- Motley Fool
Why Neurocrine Biosciences Stock Is Jumping Today
Strong second-quarter results announced after the close Monday boosted market optimism about this small biotech.
- Investor's Business Daily
Dow Jones Futures: Beyond Meat Leads 5 Key Movers; Apple Earnings Loom
Dow Jones futures: Beyond Meat stock dived late on mixed results and a share offering. RingCentral, Chegg rallied on earnings after closing in buy range. Apple earnings are on tap.
- Motley Fool
Neurocrine Biosciences Posts Sizzling Sales Growth in Q2
Sales soared for the drug Ingrezza. And key pipeline developments are on the way.
Motley FoolNeurocrine Biosciences Inc (NBIX) Q2 2019 Earnings Call Transcript
NBIX earnings call for the period ending June 30, 2019.
